NEW YORK (GenomeWeb News) — Investment bank Cowen & Co. today downgraded shares of Illumina to "Neutral" from "Outperform."

 

Reuters today reported that Cowen said the shares "appear reasonably valued, noting the firm's shares were up 154 percent year-to-date."

 

Reuters reported that the brokerage said "many investors agree with its view that Illumina's high-throughput genotyping technology is best in class."